posted
A friend told me there was someone on RB that was intentionally dumping a boat load of shares (5,000,000) and then buying them back. He aparently made a better position for himself.
Interesting that one investor could make a ripple like that.
PAUL
quote:Originally posted by keithsan: Anyone have any clue on why the drop to .023 today?
Sales should start on Tues or Wed at German convention.
I have the feeling I am missing something. This is also a pink and I have not bid/ask on my ameritrade streamer!
Thanks to anyone who can help,
Keith
------------------ But godliness with contentment is great gain. For we brought nothing into this world, and it is certain we can carry nothing out.
[This message has been edited by PAUL (edited March 12, 2004).]
I read LBTT on RB all the time. He said he made only $450 bucks. He was doing some test to see if he could flip the price or something and said the stock held up like he thought. Him and his group have millions of LBTT shares. I think 60 or so million shares.
I read LBTT on RB all the time. He said he made only $450 bucks. He was doing some test to see if he could flip the price or something and said the stock held up like he thought. Him and his group have millions of LBTT shares. I think 60 or so million shares.
BB
------------------ But godliness with contentment is great gain. For we brought nothing into this world, and it is certain we can carry nothing out.
posted
Frank M. Clark Joins Lifeline BioTechnologies as Senior Marketing and Sales Consultant Monday March 15, 10:35 am ET
RENO, Nev.--(BUSINESS WIRE)--March 15, 2004--Jim Holmes, CEO of Lifeline BioTechnologies Inc. (trading symbol LBTT) today announced that Frank M. Clark has been retained as the company's senior marketing and sales consultant for all product lines and has already begun working on behalf of Lifeline. Formerly officer and director of several Fortune 500 companies in the health care industry, Clark was executive vice president and a director of Johnson & Johnson's Medical Electronics ventures which manufactured and marketed cardiac pacemakers and nerve stimulators. Prior to that position, Clark was vice president and a director of Ethicon Inc., the leading wound closure company and a wholly owned subsidiary of Johnson & Johnson Inc. (NYSE:JNJ - News). Also, Clark was president of R. P. Scherer Inc. a major producer of soft gelatin capsules, establishing the company's presence in the Far East while enhancing Scherer's markets in Europe, North, and South America. Over the years, Clark has earned a reputation as a superior group motivator, and has a significant track record of new business start-ups as well as turn-arounds. He has appeared on national television and radio as an advocate of career self management. Frank Clark resides in Sarasota, Fla. with his family.
Stated Dr. Bill Reeves, founder and president of Lifeline BioTechnologies, "We could not be more delighted with having Frank Clark joining our organization. His professional background and experience, especially with regard to the medical products arena, is extremely rich and feel fortunate to have Frank coming on board. We welcome him most enthusiastically and anticipate a significant contribution he will be making, especially in the marketing and sales of the Mastascope product to the U.S. market. In that this is a most timely juncture in the company's history, we feel Frank Clark is perfectly suited for the job."
Reeves indicated that Clark will be attending the upcoming Breast Surgeon Conference March 31 to April 3 in Las Vegas, of which Lifeline will be attending and making Mastascope product presentations during the conference.
posted
Dont forget the BIG GUN they hired and the fact the Big marketing gun accepted the job. That would not have happened if they had much doubt that FDA approval was certain and the Demand in US would be Nation Wide. So here is looking up you ol Nipple Still may have weeks for the Big News. Any news though about sales overseas will be impportant to establish demand.
Posts: 1068 | From: Utah and Put-In-Bay Ohio | Registered: Jan 2004
| IP: Logged |
posted
latest Lifeline's Mastascope Introduced at the National Cancer Institute in Cairo, Egypt Tuesday June 29, 9:30 am ET Company's Senior Clinical Consultant Utilizes Mastascope in Patients
RENO, Nev.--(BUSINESS WIRE)--June 29, 2004--Jim Holmes, CEO Lifeline Biotechnologies, Inc. (OTC:LBTT - News) today announced that its MastaScope(TM) System, for the early detection of breast abnormalities that can become cancerous, was introduced June 28, 2004 and demonstrated at the National Cancer Institute (NCI) in Cairo, Egypt. As reported by Carlo Micheletti, Lifeline's Director of International Marketing and Sales, "Attending the demonstration were approximately 100 oncology surgeons, breast cancer specialists and radiologists from Cairo and surrounding areas, three from Saudi Arabia and two from Turkey. The program was simulcast via TV to several other hospitals throughout Egypt." Dr. Kefah Mokbel, Lifeline's senior clinical consultant, began the presentation with information about the latest advances in breast cancer, followed by slides on Mammary Ductoscopy. The program continued with two live cases performed in a side room of the auditorium. These patients were referred to the NCI for further examination and prognosis by their primary care physicians. The patients exhibited breast abnormalities that include pathological nipple discharge (PND), an early warning sign of breast cancer. The procedure, assisted by medical personnel of the NCI, was projected onto the theater screen for the audience's viewing.
Posts: 638 | From: new york | Registered: Jun 2003
| IP: Logged |
posted
This is virtually the same PR that QBID put out, but incase you aren't watching QBID and hadn't checked the news wires...
Monday May 10, 9:01 am ET
RENO, Nev.--(BUSINESS WIRE)--May 10, 2004--Jim Holmes, CEO of Lifeline Biotechnologies, Inc., (OTC:LBTT - News) responding to inquiries by shareholders, advised today that management of the Company knows of no valid business or economic reason for the recent decline in the per share price of the Company's common stock. ADVERTISEMENT
Holmes went on to say, "All markets suffer from volatility, and this is especially true on the Pink Sheets. Our stock has had a long steady climb over the past year with a number of peaks and valleys in between. As most of our investors are aware, Lifeline has been a long time target of short sellers, including large volumes of illegal naked short selling, which over the long haul has been a major contributor as a depressant on the price of our shares. However, also over this period, we have announced some of the most significant achievements in our history, and we believe these bear, to a great degree, in the growth of our share value.
"It was our expectation that our problems with the short sellers would be reduced, and eventually eliminated, when the SEC and NASD issued new rules and regulations to block illegal activities within short selling. It would appear, however, that as of yet these rules have not been effective, because the short abuses have not stopped. As a matter of fact, it appears in some respect they have only gotten worse. For the past three weeks market makers who appear to be most exposed by the short positions in Lifeline stock have extended their illegal activities to selectively excluding the processing of large purchase orders for our stock. We are currently reviewing with legal counsel the steps we can take to deal with these latest activities."
Holmes continued, "By way of review, I would like to reiterate some the major accomplishments that we have communicated to the financial community over the past six months. These include:
1. Our recent R&D accomplishments for our First Warning System(TM) which assists in the early detection of breast cancer. Specifically, Dr. Reeves' discovery that different breast lesions appear to have their own specific chaotic wave forms which have never been seen before. These findings will be the subject of a lecture Dr. Reeves has been asked to give at the upcoming International Conference on Cancer and Rhythm this fall.
"Dr. Louis Keith, the company's medical director, is also an invited speaker to the conference.
"Dr. Reeves has had several clinical papers accepted for publication concerning various critical phases of cancer development that raise several questions about present day detection of breast cancer. The company has prepared several patent applications to protect these new discoveries.
2. Our sales and marketing efforts are reality. We have had two major sales training seminars and now have sales representation in most major medical markets in the US. US product sales orders have been received and shipments have begun.
"As a result of our recent introduction of our MastaScope(TM) at the European Breast Cancer Conference in Hamburg, our International Director of Marketing and Sales, Carlo Micheleti, is attending a special meeting of the Egyptian National Cancer Institute this week to present Lifeline's MastaScope(TM) technology and products. In June he will attend a conference in Croatia and expects several orders. In July, Carlo will attend the InterAmerican Breast Conference in Cancun.
"Further, as a result of attending the Breast Surgeon's Conference in Las Vegas last month, US shipments of MastaScopes(TM) have begun.
"We expect to meet our sales goals and be running at an annual rate of $5 million by the end of this year. This rate of sales could be at a profitable level.
3. Funding - Regarding additional funding, the Company has one firm offer and several pending offers. Senior management will be in New York this week to explore several additional alternative sources.
4. The financial audit is underway and should conclude in June. Following the completion of the audit, management anticipates a filing with the SEC. Once the filing is cleared by the SEC, management expects to apply for a listing on the OTC-BB.
"Though all of the risks are not behind us, our Company is stronger right now than we have ever been. We believe what you are seeing in our share price is a last ditch and desperate attempt by the short sellers to convince our investors that they will win and the company will lose.
"Believe me, they are wrong. We are winning: The signs are all around us. We have struggled for a long time and the results of our efforts are coming to fruition. We will win and the shorts will lose."
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and subject to the safe harbor created by the Act. All statements contained in the foregoing are forward-looking statements that may involve risks and uncertainties.
-------------------------------------------------------------------------------- Contact: Lifeline Biotechnologies Jim Holmes, 775-324-1933 jholmes@lbti.com or Stock Enterprises (Investor Relations) Jim Stock, 866-242-2405 stockenter@aol.com
-------------------------------------------------------------------------------- Source: Lifeline Biotechnologies, Inc.
posted
Well, that's what you get when MMs are allowed short LBTT stock into the abyss. Once Lifeline moves to the OTCBB, we should see *some* relief some of these types of illegalities.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
